Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma

Human Pathology

Volumn 43, Issue 11, 2012, Pages 1982-1990

  Edeline, Julien ^a,b   Mottier, Stéphanie ^b   Vigneau, Cécile ^b,c   Jouan, Florence ^b   Perrin, Christophe ^a   Zerrouki, Selim ^c   Fergelot, Patricia ^b,d   Patard, Jean Jacques ^b,c   Rioux Leclercq, Nathalie ^b,c  

^a Eugène Marquis Comprehensive Cancer Center   (France)

^b CNRS   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenesis; Antiangiogenic drugs; Clear cell renal cell carcinoma; Histopathology; Prognosis

Indexed keywords

ACETYL TRANSFERASE 8; ACYLTRANSFERASE; ACYLTRANSFERASE 8B; CARBONATE DEHYDRATASE IX; PLATELET DERIVED GROWTH FACTOR D; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MUTATION; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

CARCINOMA, RENAL CELL; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEPHRECTOMY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84867863062     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.01.023     Document Type: Article

References (35)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
3. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
4. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
5. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
6. J.J. Patard, P. Fergelot, and P.I. Karakiewicz Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma Int J Cancer 123 2008 395 400
7. S. Fukata, K. Inoue, and M. Kamada Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma Cancer 103 2005 931 942
8. P. Schraml, A. Hergovitz, and F. Hatz Relevance of nuclear and cytoplasmic von Hippel Lindau protein expression for renal carcinoma progression Am J Pathol 163 2003 1013 1020
9. M.H.T. Bui, D. Seligson, and K. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma Clin Cancer Res 9 2003 802 811
10. P.B. Vermeulen, G. Gasparini, and S.B. Fox Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours Eur J Cancer 38 2002 1564 1579
11. S. Théoleyre, S. Mottier, D. Masson, and M.G. Denis HtrA3 is regulated by 15-deoxy-Delta12,14-prostaglandin J2 independently of PPARgamma in clear cell renal cell carcinomas Biochem Biophys Res Commun 394 2010 453 458
12. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
13. X. Yao, C.N. Qian, and Z.F. Zhang Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications Clin Cancer Res 13 2007 161 169
14. I. Helfrich, I. Scheffrahn, and S. Bartling Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 2010 491 503
15. N. Rioux-Leclercq, P. Fergelot, and S. Zerrouki Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases Hum Pathol 38 2007 1489 1495
16. A.M. Jubb, A. Cesario, and M. Ferguson Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases Brit J Cancer 104 2011 1877 1881
17. J.R. Gnarra, K. Tory, and Y. Weng Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
18. A.J. Pantuck, G. Zeng, A.S. Belldegrun, and R.A. Figlin Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway Clin Cancer Res 9 2003 4641 4652
19. L. Gossage, and T. Eisen Alterations in VHL as potential biomarkers in renal-cell carcinoma Nat Rev Clin Oncol 7 2010 277 288
20. B.I. Rini, E. Jaeger, and V. Weinberg Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status BJU Int 98 2006 756 762
21. T.K. Choueiri, S.A.J. Vaziri, and E. Jaeger von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 2008 860 866
22. C.N. Qian, D. Huang, B. Wondergem, and B.T. Teh Complexity of tumor vasculature in clear cell renal cell carcinoma Cancer 115 2009 2282 2289
23. E. Sabo, A. Boltenko, Y. Sova, A. Stein, S. Kleinhaus, and M.B. Resnick Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma Clin Cancer Res 7 2001 533 537
24. M. Tomisawa, T. Tokunaga, and Y. Oshika Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma Eur J Cancer 35 1999 133 137
25. D. Yilmazer, Ü. Han, and B. Önal A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma Int Urol Nephrol 39 2006 691 698
26. M. Raica, A.M. Cimpean, and A. Anghel Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma Neoplasma 54 2007 278 284
27. S.B. Fox, R.D. Leek, M.P. Weekes, R.M. Whitehouse, K.C. Gatter, and A.L. Harris Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis J Pathol 177 1995 275 283
28. A.R. Brannon, A. Reddy, and M. Seiler Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns Genes Cancer 1 2010 152 163
29. T. Klatte, D.B. Seligson, and J. LaRochelle Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy Cancer Epidemiol Biomarkers Prev 18 2009 894 900
30. D. Wuttig, B. Baier, and S. Fuessel Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient Int J Cancer 125 2009 474 482
31. M. Yao, Y. Huang, and K. Shioi A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma Int J Cancer 123 2008 1126 1132
32. M. Tremmel, A. Matzke, and I. Albrecht A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis Blood 114 2009 5236 5244
33. C.H. Heldin, and B. Westermark Mechanism of action and in vivo role of platelet-derived growth factor Physiol Rev 79 1999 1283 1316
34. J.C. Chambers, W. Zhang, and G.M. Lord Genetic loci influencing kidney function and chronic kidney disease Nat Genet 42 2010 373 375
35. P. Juhanson, K. Kepp, and G. Veldre N-acetyltransferase 8, a positional candidate for blood pressure and renal regulation: resequencing, association and in silico study BMC Med Genet 9 2008 25